Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial
2026年6月12日 更新者：City of Hope Medical Center
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma.
Surgical margins are one of the criteria used in assessing the effectiveness of a given surgical procedure.
They are the edges or border of the tissue removed in cancer surgery.
A negative margin means that the resected tumor is surrounded by normal tissue, which implies there is no disease left in the patient.
By contrast, a positive margin means that sarcoma cells are visible at the edge of the tumor.
Positive margins may be classified as planned when they are expected pre-operatively due to the preservation of a critical structure, or unexpected when the pathologist reports the presence of tumor at the margin despite the surgeon having intended to remove it in its entirety.
Fluorescence-guided surgery is an established surgical method that involves the administration of fluorescent dye (in this case, indocyanine green) into the tumor, which can then be visualized with a special camera during surgery to help surgeons identify tumor versus healthy tissue.
Fluorescence-guided surgery may reduce the rate of unexpected positive margins in patients undergoing surgery for sarcoma.
調査の概要
状態
まだ募集していません
詳細な説明
PRIMARY OBJECTIVE:
I. To determine whether there is a reduction in the unexpected positive margin rate (UPM) in patients receiving fluorescence-guided surgery (FGS) using indocyanine green (ICG) compared to standard of care (SoC).
SECONDARY OBJECTIVE:
I. To determine the effect of FGS using ICG compared to the SoC over a 12-month period.
EXPLORATORY OBJECTIVE:
I. To determine the role of ICG in the pathological margin assessment of resected sarcoma specimens whilst improving understanding of the cellular mechanisms of FGS using ICG.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo standard of care surgical resection.
ARM II: Patients receive ICG intravenously (IV) 12-24 hours prior to their scheduled surgery. Patients then undergo FGS with intraoperative fluorescence imaging.
After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months.
研究の種類
介入
入学 (推定)
22
段階
- フェーズ2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope Medical Center
-
コンタクト：
- Thinzar Lwin
- 電話番号：626-218-3880
- メール：tlwin@coh.org
-
主任研究者：
- Thinzar Lwin
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Documented written informed consent of the participant
- Histologically confirmed diagnosis of intermediate to high grade sarcoma
- All ages
- Amenable to surgical resection as a part of curative intent for the patient
Willingness to:
- Respond to surveys during the trial
- Permit medical record/ clinical laboratory result review
Exclusion Criteria:
- Due for surgery with palliative intent
- Recurrent tumors
- Intracranial, retroperitoneal, and visceral anatomical locations
- A woman of childbearing potential who is currently pregnant (as confirmed by urine pregnancy test)
- A woman who are currently breastfeeding
- Known allergies to ICG, iodine, iodine dyes or shellfish
- Unable to provide written and informed consent
- Patients with hyper-thyroidism or autonomic thyroid adenomas
- Premature infants/neonates with exchange transfusion indication due to hyperbilirubinemia
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Arm I (standard of care)
Patients undergo standard of care surgical resection.
|
補助研究
外科的切除を受ける
他の名前：
補助研究
|
|
実験的：Arm II (FGS)
Patients receive ICG IV 12-24 hours prior to their scheduled surgery.
Patients then undergo FGS with intraoperative fluorescence imaging.
|
補助研究
補助研究
蛍光イメージングを受ける
与えられた IV
他の名前：
Undergo FGS
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Unexpected positive margin (UPM) rate
時間枠：At 6 months post-surgery
|
The margin status of each tumor will be taken from the pathology report for each patient enrolled in the trial.
This will be recorded at six months post- surgery and will be classified according to the R classification system.
The UPM rate for each arm will be defined by calculating the percentage of patients in that arm with a UPM on histopathological assessment of the resection specimen.
The percentage of patients with unexpected positive margins will be calculated for each group to give the unexpected positive margin rate.
This will then be compared between the two groups.
Will use a logistic regression that adjusts key covariates including stratification factors used in the randomization.
A Wald test and a 95% confidence interval will be extracted from this model.
A two-sided p-value will be found from the Wald test.
|
At 6 months post-surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Intraoperative complications
時間枠：During surgical resection
|
Intraoperative complications may include blood loss requiring transfusion, inadvertent damage to nerves, inadvertent damage to tendons/ligaments, inadvertent damage to bony structures, myocardial infarction, stroke, other events determined by the principal investigator to be a complication of the surgery.
Will be compared between the two groups at the day of operation.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
During surgical resection
|
|
Postoperative complications
時間枠：Up to 12 months
|
Postoperative complications may include wound infection, wound dehiscence, seroma, flap complications, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, other events determined by the principal investigator to be a complication of the surgery.
Post operative complications will be graded using the Calvien Dindo Classifications of Surgical Complications.
Will be compared between the two groups at the day of operation and at 1-, 6- and 12-month follow-up time points.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Up to 12 months
|
|
Length of index operation
時間枠：During surgical resection
|
Will be measured in minutes.
Will be compared between groups on the day of operation.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
During surgical resection
|
|
Length of inpatient stay
時間枠：Through study completion, an average of 1 year
|
Will be measured in days.
Will be compared between the two groups at the day of operation and at 1-, 6- and 12-month follow-up time points.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Through study completion, an average of 1 year
|
|
Recurrence
時間枠：Up to 12 months
|
Local/regional/distal recurrence is defined as the recurrence of sarcoma at the site of primary resection (local) or at a site other than that of the primary tumor, including distal metastasis.
Investigations must be tailored to circumstances but where possible should include histological confirmation.
Will be compared between the two groups at the 12-month time point.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Up to 12 months
|
|
Therapies
時間枠：Up to 12 months
|
Adjuvant and neo-adjuvant therapy rates will include radiation therapy and/or chemotherapy.
The type and frequency of therapy will be recorded.
Will be compared between groups on the day of operation.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Up to 12 months
|
|
Overall survival
時間枠：Up to 12 months
|
Overall survival is defined as death due to any cause.
Where possible, the specific cause of death should be documented, allowing the calculation of disease specific survival.
Will be compared between the two groups at the 12-month time point.
Descriptive analysis will be performed to analyze the nature of the data.
Survival analysis like the Kaplan-Meier statistics will be used to find the overall survival in each arm.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Up to 12 months
|
|
Quality of life
時間枠：Up to 12 months
|
Quality of life will be assessed using the EQ-5D-5L European Quality of Life Five Dimension Five Level scale or European Quality of Life Five Dimension Three Level Youth scale.
Will be compared between the two groups.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Up to 12 months
|
|
Recovery following resection
時間枠：Up to 12 months
|
After undergoing surgical resection for sarcomas of the extremity, participants are often left with an element of functional impairment in the affected limb due to the extent of the resection required.
There are separate questionnaires for participants undergoing surgery on the upper and lower extremities, in which participants are asked to rate their ability to perform several tasks, rating them from 'impossible' to 'not at all difficult', as well as overall rating of how disabled they feel they are.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Up to 12 months
|
|
Surgical impact and decision making
時間枠：Immediately following surgical resection
|
Immediately following the surgical procedure, a surgical case report form (CRF) will be completed by the surgeon who performed the surgery.
This CRF will record if there was the potential for an acceptable close/positive margin due to the preservation of a critical structure, the length of the operation and any intra-operative complications.
If the participant was randomized to the intervention arm, the CRF will also record whether the surgeon felt this influenced their operative decision making.
Descriptive analysis will be performed to analyze the nature of the data.
Secondary outcomes with binary/multiple measures will be analyzed with logistic regression.
For variables with continuous measure, appropriate regression models will be used.
Appropriate statistical tests depending on the nature of the variables (whether qualitative or quantitative) will be used for comparison between the two treatment arms.
|
Immediately following surgical resection
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Thinzar Lwin、City of Hope Medical Center
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2027年5月15日
一次修了 (推定)
2028年5月11日
研究の完了 (推定)
2028年5月11日
試験登録日
最初に提出
2026年6月9日
QC基準を満たした最初の提出物
2026年6月12日
最初の投稿 (実際)
2026年6月16日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月16日
QC基準を満たした最後の更新が送信されました
2026年6月12日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 24374 (その他の識別子：City of Hope Medical Center)
- P30CA033572 (米国 NIH グラント/契約)
- NCI-2026-03865 (レジストリ識別子：CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
アンケート管理の臨床試験
-
Fondazione Poliambulanza Istituto Ospedalieroわからない
-
Fondation Santé des Étudiants de Franceまだ募集していません思春期の行動 | メンタルヘルスの問題
-
Assistance Publique - Hôpitaux de Paris完了
-
Centre Georges Francois Leclerc積極的、募集していないステージ IV の非小細胞気管支肺癌であり、現在のフランスの推奨に従って第一選択治療の恩恵を受けるフランス
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridgeわからない筋骨格疾患 | 筋骨格系損傷
-
Centre Hospitalier Universitaire de Nīmes完了
-
Assistance Publique - Hôpitaux de Parisまだ募集していません